<DOC>
	<DOCNO>NCT00379405</DOCNO>
	<brief_summary>Study efficacy Saquinavir/Ritonavir give single therapy maintenance therapy , compare standard HAART therapy .</brief_summary>
	<brief_title>Saquinavir/Ritonavir Single Therapy Maintenance Treatment</brief_title>
	<detailed_description>Different therapeutic strategy investigate improve adherence treatment reduce toxicity . Both reduction number dose number daily tablet lead improvement therapeutic compliance . Similarly , administration new treatment regimen reduce number tablet day without NTRI may clinically useful improve compliance HAART limit NTRI-associated toxicity . These would comprise combination PI , boost ritonavir , plus non-Nucleoside single therapy PIs boost ritonavir . In regard , result obtain lopinavir/ritonavir atazanavir/ritonavir promise open possible channel research PIs boost low dos ritonavir . There PIs whose antiretroviral efficacy also demonstrate , saquinavir , whose economic cost much low . Furthermore , saquinavir low toxicity profile , availability saquinavir 500 mg facilitates comfortable administration , since make possible reduce number daily tablet half . Moreover , important take account incidence mutation confer resistance saquinavir patient fail combination include PI low , make possible reuse drug future treatment regimen salvage patient PI All characteristic ( high intrinsic potency , low number tablet , low toxicity , low potential selection resistant viral strain combination ritonavir , low economic cost ) make single therapy new formulation saquinavir , boost low dos ritonavir , possible therapeutic option maintenance strategy HIV-infected patient maintain suppression viral load .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<criteria>Patients infect HIV1 ( least one document positive WesternBlot ) . Age &gt; 18 year . Patients antiretroviral treatment ( standard HAART therapy ) least six month . HIV1 plasma viral load &lt; 50 copies/mL ( document least two determination perform six month prior inclusion visit ) . Patients without evidence previous virological failure IP Absence opportunistic infection and/or tumour three month prior inclusion . Subject able follow treatment period , without suspicion poor adherence previous antiretroviral treatment . Signature informed consent . Suspicion unsuitable antiretroviral treatment compliance . Documented existence primary mutation protease gene 3 following : L10F/I/R/V , K20M/R , M36I/V , I54L/T/V , L63P , A71T/V , V82A/F/T/S , I84A/V OR L90M . Known allergic hypersensitivity investigational drug similar drug . Hepatic test ( AST , ALT , GGT ) &gt; equal 5 time upper limit normality three month prior screen visit Presence renal impairment ( creatinine &gt; equal 1.5 time upper limit normality ) . Pregnancy breastfeed . Refusal use reliable contraceptive method study period . Participation another clinical trial wich entail antiretroviral treatment modification .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Saquinavir/ritonavir</keyword>
	<keyword>Single therapy</keyword>
	<keyword>Virological efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>HIV-1</keyword>
</DOC>